Documentos de Fleseriu M. | REDI

Regresar

Mostrando 4 resultados de: 4

Filtros aplicados

Objetivos de Desarrollo Sostenible: "ODS 5: Igualdad de género"

Subtipo de publicación

Publisher

European Journal of Endocrinology(2)

Expert Review of Endocrinology and Metabolism(1)

The Lancet Diabetes and Endocrinology(1)

Área temáticas

Enfermedades(4)

Farmacología y terapéutica(2)

Problemas sociales y servicios a grupos(1)

Salud y seguridad personal(1)

Área de conocimiento

Medicina interna(3)

Objetivos de Desarrollo Sostenible

ODS 10: Reducción de las desigualdades(4)

ODS 3: Salud y bienestar(4)

Año de Publicación

Origen

Palabras Claves

Cushing’s disease(1)

Cushing’s syndrome(1)

Ketoconazole(1)

levoketoconazole(1)

Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial

Abstract: Background: Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing'

Palabras claves:

Biller B.M.K., Cohen F., Elenkova A., Feelders R.A., Fleseriu M., Geer E.B., Greenman Y., Pivonello R., Richard J. Auchus, Salvatori R., Witek P.

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes

Abstract: Objective: This extended evaluation (EE) of the SONICS study assessed the effects of levoketoconazol

Palabras claves:

Biller B.M.K., Buchfelder M., Cohen F., Feldt-Rasmussen U., Fleseriu M., Geer E.B., Greenman Y., Heaney A.P., Kennedy L., Pivonello R., Richard J. Auchus, Salvatori R., Zacharieva S.

Levoketoconazole: a novel treatment for endogenous Cushing's syndrome

Abstract: Introduction: Endogenous Cushing’s syndrome (CS) is a rare, life-threatening endocrine disorder that

Palabras claves:

cortisol, Cushing’s disease, Cushing’s syndrome, Ketoconazole, levoketoconazole, medical therapy, steroidogenesis inhibitor

Biller B.M.K., Fleseriu M., Pivonello R., Richard J. Auchus, Salvatori R., Zacharieva S.

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension

Abstract: Objective: To investigate the long-term efficacy and tolerability of osilodrostat, a potent oral 11β

Palabras claves:

Belaya Z., Biller B.M.K., Feelders R.A., Fleseriu M., Houde G., Izquierdo M., Newell-Price J., Pedroncelli A.M., Pivonello R., Richard J. Auchus, Roughton M., Scaroni C., Shimatsu A., Vila G., Walia R.